CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño‐Tarragona, Nicholas C.P. Cross, Alberto Álvarez‐Larrán et al.|Blood Advances|2023Cited by 32
HLA-DPB1 MISMATCH IN HLA-A-B-DRB1 IDENTICAL SIBLING DONOR STEM CELL TRANSPLANTATION AND ACUTE GRAFT-VERSUS-HOST DISEASEDavid Gallardo, Rafael de la Cámara, Carmen Martiín et al.|Transplantation|2004Cited by 28
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?Juan Luis Steegmann, Santiago Osorio, Vicente Escudero‐Vilaplana et al.|Annals of Hematology|2018Cited by 26
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phaseJuan Manuel Alonso‐Domínguez, Joaquín Martínez‐López, Luis Felipe Casado et al.|PLoS ONE|2017Cited by 10
Leucemia mieloide crónica en España: sus características de presentación han cambiado. Sección española del registro poblacional EUTOSSantiago Osorio, Juan Luis Steegmann, Luis Casado et al.|Revista Clínica Española|2016Cited by 9